ClinicalTrials.Veeva
Menu

Find clinical trials for Kidney Disease in Phoenix, AZ

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Kidney Diseases
Chronic Renal Insufficiency
Chronic Kidney Failure
IGA Glomerulonephritis
Renal Cell Carcinoma
Renal Insufficiency
Carcinoma

Kidney Disease trials near Phoenix, AZ, USA:

Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease

will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney...

Enrolling
Hyperphosphatemia Related to Chronic Kidney Disease
Drug: ferric citrate

Phase 3

Keryx Biopharmaceuticals

Phoenix, Arizona, United States and 12 other locations

Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects with Hypertension and Chronic Kidney Disease (CKD) with Albuminuria

This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and...

Enrolling
Chronic Kidney Disease
Drug: Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD
Drug: Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD

Phase 2

Mineralys Therapeutics

Phoenix, Arizona, United States and 43 other locations

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure (BaxDuo-Pacific)

and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney...

Begins enrollment in 1 month
Chronic Kidney Disease and Hypertension
Drug: Baxdrostat/dapagliflozin
Drug: Placebo/dapagliflozin

Phase 3

AstraZeneca
AstraZeneca

Surprise, Arizona, United States and 319 other locations

A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease

To assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV)* To characterize the pharmacokinetic (PK) properties of RGLS...

Enrolling
Polycystic Kidney, Autosomal Dominant
Autosomal Dominant Polycystic Kidney Disease
Drug: Placebo
Drug: RGLS8429

Phase 1

Regulus Therapeutics

Mesa, Arizona, United States and 27 other locations

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney...

Active, not recruiting
Chronic Kidney Disease With High Proteinuria
Drug: Dapagliflozin
Drug: Zibotentan/Dapagliflozin

Phase 3

AstraZeneca
AstraZeneca

Sun City West, Arizona, United States and 295 other locations

A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP (TRANQUILITY)

CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 (also known as pacibekitug) in participants with chronic kidney...

Active, not recruiting
Kidney Insufficiency, Chronic
Chronic Kidney Diseases
Drug: TOUR006 - 25 MG
Drug: TOUR006 - 50 MG

Phase 2

Tourmaline Bio

Phoenix, Arizona, United States and 48 other locations

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes (CONFIDENCE)

receptor is known to trigger injury and inflammation in the kidney and is therefore thought to play a role in CKD.Empagliflozin lowers blood...

Active, not recruiting
Chronic Kidney Disease
Type 2 Diabetes Mellitus
Drug: Finerenone (BAY94-8862 ) 20 mg
Drug: Finerenone Placebo

Phase 2

Bayer
Bayer

Surprise, Arizona, United States and 189 other locations

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease (AMPLITUDE)

tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney...

Enrolling
Proteinuric Kidney Disease
Drug: Placebo
Drug: VX-147

Phase 2, Phase 3

Vertex Pharmaceuticals
Vertex Pharmaceuticals

Phoenix, Arizona, United States and 301 other locations

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria (FIONA OLE)

Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney...

Enrolling
Chronic Kidney Disease
Proteinuria
Drug: Finerenone (Kerendia, BAY94-8862)

Phase 3

Bayer
Bayer

Phoenix, Arizona, United States and 145 other locations

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria (FIONA)

Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney...

Enrolling
Chronic Kidney Disease
Proteinuria
Drug: Finerenone (Kerendia, BAY94-8862)
Drug: Placebo

Phase 3

Bayer
Bayer

Phoenix, Arizona, United States and 143 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems